Replies to post #2424 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC fully-diluted shares @3/31/22=90.9M—an increase of 2.6M shares since 2/17/22 (#msg-168050573).

The 90.9M figure mentioned above consists of: 71.8M basic shares on the 3/31/22 balance sheet (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000119312522146362/d327432d10q.htm#id375bd61c7fe4ceea8c0261ee845a3ae_16 ); 5.1M options (ibid p.23); 5.1M shares of unvested restricted stock (ibid p.23); and 8.9M shares deriving from the convertible debt issued in Feb 2020.

(Excluding the shares derived from the convertible debt, fully-diluted shares at 3/31/22 were 82.0M.)